Key facts
- Stablepharma’s last known valuation is $72.2M (Dec 2024).
- It has raised $10.5M; the latest was Grant ($2.6M) in Feb 2025.
- Notable investors include Innovate UK, European Innovation Council, SFC Capital, Ascension, Ascension Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Stablepharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Stablepharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Stablepharma
Developer of a thermostability technology designed to improve the stability and accessibility of temperature-sensitive vaccines. The company offers advanced formulation and preservation methods, enabling vaccine manufacturers, academic institutions, and global health organizations to improve distribution efficiency and reduce dependence on cold storage.
- Sector
- Healthcare
- HQ
- Bath, United Kingdom
- Founded
- 2012
- Employees
- 24
- Website
- stablepharma.com/
- Ownership
- Privately Held (backing)
Stablepharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stablepharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stablepharma in its N-PORT filings yet. We sweep new filings monthly.